Emerging cystic fibrosis pathogens: Incidence and antimicrobial resistance

New Microbiologica

Volumn 30, Issue 1, 2007, Pages 59-62

  Magni, Annarita ^a   Giordano, Alessandra ^a   Mancini, Carlo ^a   Pecoraro, Claudia ^b   Varesi, Paola ^a   Quattrucci, Serena ^b   Trancassini, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Antibicrobial resistence; Bacteria isolation; Cystic fibrosis

Indexed keywords

ANTIINFECTIVE AGENT;

ACHROMOBACTER; ADOLESCENT; ANTIBIOTIC RESISTANCE; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; INCIDENCE; ITALY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; REVIEW; XANTHOMONADACEAE;

ACHROMOBACTER; ADOLESCENT; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; ITALY; MICROBIAL SENSITIVITY TESTS; XANTHOMONADACEAE;

ACHROMOBACTER XYLOSOXIDANS; BACTERIA (MICROORGANISMS); BURKHOLDERIA CEPACIA COMPLEX; STENOTROPHOMONAS MALTOPHILIA;

EID: 33847254482     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. BERINGER, P.M., APPLEMAN, M.D. (2000). Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features. Current opinion in pulmonary medicine, 6, 545-550.
2. CHMIEL, J.F., BERGER, M., KONSTAN, M.W. (2002). The role of inflammation in the pathophysiology of CF lung disease. Clinical reviews in allergy & immunology, 23, 5-27.
3. CLINICAL LABORATORY STANDARDS INSTITUTE. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement M100-S16. Wayne Pa USA; (2006).
4. CYSTIC FIBROSIS FOUNDATION. Patient registry 2001. Annual Data Report to the Center Directors. Bethesda,MD: Cystic Fibrosis Foundation; (2002).
5. DEMKO, C.A., STERN, R.C., DOERSHUK, C.F. (1998). Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatric pulmonology, 25, 304-308.
6. DENTON, M., KERR, K.G. (1998). Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical microbiology reviews, 11, 57-80.
7. GIBSON, R.L., BURNS, J.L., RAMSEY, B.W. (2003). Pathophysiology and management of pulmonary infection in cystic fibrosis. American journal of respiratory and critical care medicine, 168, 918-951.
8. GOSS, C.H., OTTO, K., AITKEN, M.L., RUBENFELD, G.D. (2002). Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. American journal of respiratory and critical care medicine, 166, 356-361.
9. GRAFF, G.R., BURNS, J.L. (2002). Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest, 121, 1754-1760.
10. HENRY, D., CAMPBELL, M., MC GIMPSEY, C. CLARKE, A., LOUDEN, L., BURNS, J.L., ROE, M.H., VANDAMME, P., SPEERT, D. (1999). Comparison of isolation media for recovery of Burkholderia cepacia complex fom respiratory secretions of patients with cystic fibrosis. Journal of clinical microbiology, 37, 1004-1007.
11. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. Performance standards for antimicrobial disk susceptibility tests, vol.20, no1. NCCLS Document. National Committee for Clinical Laboratory Standards, Wayne Pa USA; (2000).
12. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. Performance standards for antimicrobial disk susceptibility testing: fourteenth informational supplement M100-S14. Wayne Pa USA; (2004).
13. STEINKAMP, G., WIEDERMANN, B., RIETSCHEL, E., KRAHL, A., GIELEN, J., BARMEIER, H., RATJEN, F., EMERGING BACTERIA STUDY GROUP. (2005). Prospective evaluation of emerging bacteria in cystic fibrosis. Journal of cystic fibrosis, 4, 41-48.
14. TALMACIU, I., PARLOTTA, L., MORTENSEN, J., SCHIDLOW, D.V. (2000). Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatric pulmonology, 30, 10-15.
15. TAN, K., CONWAY, S.P., BROWNLEE, K.G., ETHERINGTON, C., PECKHAM, D.G. (2002). Alcaligenes infection in cystic fibrosis Pediatric pulmonology, 34, 101-104.